✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Novo Nordisk A/S

Common Name
Novo Nordisk
Country
Denmark
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
68,794
Ticker
NOVO B
Exchange
NASDAQ COPENHAGEN A/S
Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabe...

Novo Nordisk's GHG Emissions Data Preview

In 2025, Novo Nordisk completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Novo Nordisk has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)202520242023
2022 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
Tracenable value for the metrica
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
Location-Based
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
Copy/Paste is a PRO feature.
Tracenable value for the metric
0000000
Unspecified Calculation Method
Copy/Paste is a PRO feature.
Tracenable value for the metric
0000000
Copy/Paste is a PRO feature.
Tracenable value for the metric
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Tracenable value for the metrica
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
Tracenable value for the metrica
Copy/Paste is a PRO feature.
Tracenable value for the metrica
0000000
Limited Data Preview
You are viewing a limited preview of Novo Nordisk’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2019, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=NOVO B&reporting_period=2025"

Verified Sources Behind Novo Nordisk’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Novo Nordisk’s data sources below and access millions more through our Disclosure Search.

a. Novo Nordisk's Annual Report 2025
b. Novo Nordisk's Integrated Report 2021

Insights into Novo Nordisk's Operational Emissions

In 2025, the total operational greenhouse gas (GHG) emissions of Novo Nordisk amounted to 318,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2024, the total operational greenhouse gas (GHG) emissions of Novo Nordisk increased by 22.78%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Novo Nordisk's Scope 1 Emissions Over Time

2019202020212022202320242025030 k60 k90 k120 ktCO2e-13%+3%-1%+3%+9%+41%
  • Total Scope 1
  • Year-over-Year Change

What are Novo Nordisk's Scope 1 emissions?

In 2025, the total Scope 1 emissions of Novo Nordisk were 120,000 metric tons of CO₂ equivalent (tCO₂e).a

Has Novo Nordisk reduced its Scope 1 emissions over time?

Since 2019, Novo Nordisk's Scope 1 emissions have increased by 39.53%, reflecting a rising long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2024), Novo Nordisk's Scope 1 emissions increased by 41.18%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Novo Nordisk's Scope 2 emissions?

In 2025, Novo Nordisk reported Scope 2 greenhouse gas (GHG) emissions of 63,000 tCO₂e using the market-based method and 198,000 tCO₂e using the location-based method.a

Has Novo Nordisk reduced its Scope 2 emissions over time?

Compared to the previous year (2024), Novo Nordisk's Scope 2 emissions (Location-Based) rose by 13.79% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya

What methodology does Novo Nordisk use for Scope 2 reporting?

In 2025, Novo Nordisk reported its Scope 2 emissions using the market-based method and using the location-based method.a

Novo Nordisk's Scope 2 Emissions Over Time

2019202020212022202320242025050 k100 k150 k200 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Novo Nordisk's Value Chain Emissions

In 2025, Novo Nordisk reported 2,507,000 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2025 disclosure of Novo Nordisk includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Novo Nordisk's Scope 3 Emissions Over Time

20192020202120222023202420250650 k1.3 M1.95 M2.6 MtCO2e-45%+1%+2885%-28%+24%+16%
  • Total Scope 3
  • Year-over-Year Change

What are Novo Nordisk's Scope 3 emissions?

In 2025, Novo Nordisk reported total Scope 3 emissions of 2,507,000 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 99.88% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.12% came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Novo Nordisk reduced its Scope 3 emissions over time?

Since 2019, Novo Nordisk's Scope 3 emissions have increased by 1,628.97%, reflecting a rising long-term trend in Scope 3 emissions over time.ab

Compared to the previous year (2024), Novo Nordisk's Scope 3 emissions increased by 16.06%, suggesting that the company faced challenges in reducing emissions across its value chain.a

What categories of Scope 3 emissions does Novo Nordisk disclose?

In 2025, Novo Nordisk reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This partial disclosure allows for some insight into the company's indirect impacts.

What are the main sources of Novo Nordisk's Scope 3 emissions?

In 2025, the largest contributors to Novo Nordisk's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 1,383,000 tCO₂e (55.17%)
  • Capital Goods (Cat. 2): 609,000 tCO₂e (24.29%)
  • Business Travel (Cat. 6): 190,000 tCO₂e (7.58%)

Novo Nordisk's Scope 3 Emissions by Categories

Capital Goods(Cat. 2)(24.3%)Business Travel(Cat. 6)(7.6%)Purchased Goods andServices (Cat. 1)(55.2%)

Insights into Novo Nordisk’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Novo Nordisk reported Scope 1 greenhouse gas (GHG) emissions of 120,000 tCO₂e and total revenues of USD 48,646 millions. This translates into an emissions intensity of 2.47 tCO₂e per millions USD.a

Novo Nordisk's Scope 1 Emissions Intensity Compared to Peers

5005,00050,0001,000,00010,000,000Scope 1 Emissions (tCO2e)2001,00010,00050,000200,000Revenues (Millions of USD)ZCTOBristol-Myers SquibbYear: 2024Scope 1: 206,726 tCO2eRevenue: $M 48,300Scope 1 Intensity: 4.28 tCO2e/$MBiogenYear: 2024Scope 1: 56,611 tCO2eRevenue: $M 9,676Scope 1 Intensity: 5.85 tCO2e/$MMerck KGaAYear: 2025Scope 1: 657,835 tCO2eRevenue: $M 24,809Scope 1 Intensity: 26.52 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MKalbe FarmaYear: 2024Scope 1: 19,895 tCO2eRevenue: $M 2,028Scope 1 Intensity: 9.81 tCO2e/$MZZZhangzhou Pientzehuang PharmaceuticalYear: 2023Scope 1: 2,301 tCO2eRevenue: $M 1,415Scope 1 Intensity: 1.63 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MOtsuka HoldingsYear: 2024Scope 1: 368,733 tCO2eRevenue: $M 14,840Scope 1 Intensity: 24.85 tCO2e/$MAmgenYear: 2024Scope 1: 147,000 tCO2eRevenue: $M 33,424Scope 1 Intensity: 4.40 tCO2e/$MVirbacYear: 2024Scope 1: 10,966 tCO2eRevenue: $M 1,454Scope 1 Intensity: 7.54 tCO2e/$MOrganon & CoYear: 2024Scope 1: 34,200 tCO2eRevenue: $M 6,403Scope 1 Intensity: 5.34 tCO2e/$MAbbVieYear: 2024Scope 1: 300,072 tCO2eRevenue: $M 56,334Scope 1 Intensity: 5.33 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MGSKYear: 2024Scope 1: 521,000 tCO2eRevenue: $M 39,374Scope 1 Intensity: 13.23 tCO2e/$MAstraZenecaYear: 2024Scope 1: 125,386 tCO2eRevenue: $M 39,722Scope 1 Intensity: 3.16 tCO2e/$MBayerYear: 2025Scope 1: 1,890,000 tCO2eRevenue: $M 53,581Scope 1 Intensity: 35.27 tCO2e/$MCCCSPC Pharmaceutical GroupYear: 2024Scope 1: 474,567 tCO2eRevenue: $M 3,975Scope 1 Intensity: 119.39 tCO2e/$MRoche HoldingYear: 2025Scope 1: 211,962 tCO2eRevenue: $M 79,968Scope 1 Intensity: 2.65 tCO2e/$MMerck & Co IncYear: 2024Scope 1: 721,200 tCO2eRevenue: $M 64,168Scope 1 Intensity: 11.24 tCO2e/$MRecordatiYear: 2025Scope 1: 36,557 tCO2eRevenue: $M 3,078Scope 1 Intensity: 11.88 tCO2e/$MSichuan Kelun PharmaceuticalYear: 2024Scope 1: 2,361,763 tCO2eRevenue: $M 2,989Scope 1 Intensity: 790.21 tCO2e/$MTTTong Ren Tang TechnologiesYear: 2024Scope 1: 30,000 tCO2eRevenue: $M 995Scope 1 Intensity: 30.16 tCO2e/$MKyowa KirinYear: 2024Scope 1: 16,133 tCO2eRevenue: $M 3,157Scope 1 Intensity: 5.11 tCO2e/$MOOOrion OyjYear: 2025Scope 1: 5,018 tCO2eRevenue: $M 2,221Scope 1 Intensity: 2.26 tCO2e/$MNovo NordiskYear: 2025Scope 1: 120,000 tCO2eRevenue: $M 48,646Scope 1 Intensity: 2.47 tCO2e/$M

How does Novo Nordisk's GHG emissions intensity compare to its peers?

In 2025, Novo Nordisk reported a Scope 1 emissions intensity of 2.47 tCO₂e per millions USD. Compared to the peer group median of 7.2, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Novo Nordisk rank on GHG emissions intensity within its industry?

In 2025, Novo Nordisk ranked 4 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Novo Nordisk among the top performers, with one of the lowest emissions intensities relative to peers.a

Insights into Novo Nordisk's Total Carbon Footprint

In 2025, Novo Nordisk reported a total carbon footprint of 2,825,000 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 16.78% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a

The largest contributor to Novo Nordisk's total carbon footprint was Scope 3 emissions, accounting for 88.74% of the company's total carbon footprint, followed by Scope 2 emissions at 7.01%.a

Want Full Access to Novo Nordisk's GHG Emissions Dataset?
Start 30-Day Free Trial